Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:CYTK NASDAQ:MLYS NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.53-3.2%$116.81$5.69▼$148.83$8.36B0.692.64 million shs2.62 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$2.07B0.571.55 million shs4.18 million shsPRAXPraxis Precision Medicines$254.00-4.1%$324.36$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+16.39%-18.97%-15.23%-4.02%+1,201.86%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%MLYSMineralys Therapeutics-0.04%-20.58%-14.45%-5.79%+61.40%PRAXPraxis Precision Medicines-5.08%-24.92%-20.57%-14.79%+539.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$101.53-3.2%$116.81$5.69▼$148.83$8.36B0.692.64 million shs2.62 million shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$2.07B0.571.55 million shs4.18 million shsPRAXPraxis Precision Medicines$254.00-4.1%$324.36$37.19▼$366.52$7.38B2.71445,340 shs570,041 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+16.39%-18.97%-15.23%-4.02%+1,201.86%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%MLYSMineralys Therapeutics-0.04%-20.58%-14.45%-5.79%+61.40%PRAXPraxis Precision Medicines-5.08%-24.92%-20.57%-14.79%+539.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0828.12% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3038.92% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.33108.25% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72125.48% UpsideCurrent Analyst Ratings BreakdownLatest MLYS, ABVX, PRAX, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$715.00 ➝ $616.006/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026PRAXPraxis Precision Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $650.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.00 ➝ $810.006/2/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$420.00 ➝ $374.006/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ACYTKCytokinetics$88.04M101.03N/AN/A($5.39) per share-13.26MLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/APRAXPraxis Precision Medicines$8.55M828.25N/AN/A$34.85 per share7.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest MLYS, ABVX, PRAX, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million3/12/2026Q4 2025MLYSMineralys Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25CYTKCytokineticsN/A4.214.21MLYSMineralys TherapeuticsN/A44.3344.33PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%CYTKCytokineticsN/AMLYSMineralys Therapeutics84.46%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ACYTKCytokinetics2.60%MLYSMineralys Therapeutics18.94%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.69 millionN/ANot OptionableCYTKCytokinetics250124.43 million121.20 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableMLYS, ABVX, PRAX, and CYTK HeadlinesRecent News About These CompaniesPraxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings4 hours ago | finance.yahoo.comPraxis' Premium Price May Reflect Unrealistic Market Prospects In Essential TremorJune 5 at 4:06 PM | seekingalpha.comPraxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare ConferenceJune 4 at 4:01 PM | globenewswire.comPraxis Precision Medicines (PRAX) Receives a Buy from LifeSci CapitalJune 4 at 7:35 AM | theglobeandmail.comHC Wainwright Issues Pessimistic Outlook for PRAX EarningsJune 4 at 7:14 AM | marketbeat.comGeode Capital Management LLC Acquires 105,347 Shares of Praxis Precision Medicines, Inc. $PRAXJune 4 at 3:47 AM | marketbeat.comWhat is HC Wainwright's Forecast for PRAX FY2030 Earnings?June 3 at 8:39 AM | marketbeat.comPraxis pauses one of its seizure programs after phase 2 failJune 3 at 2:39 AM | fiercebiotech.comFPraxis down on trial setback for seizure therapyJune 3 at 2:39 AM | msn.comPraxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy PipelineJune 3 at 2:39 AM | finance.yahoo.comThe shocking twist that sent this seizure-focused biotech into a diveJune 3 at 2:39 AM | msn.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2 at 4:01 PM | globenewswire.comPraxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary EndpointJune 2 at 6:09 AM | benzinga.comPraxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary EndpointJune 1, 2026 | marketwatch.comPRAX stock drops 12% after hours on trial setback — retail eyes FDA approval of other pipeline candidatesJune 1, 2026 | msn.comFDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX)June 1, 2026 | finance.yahoo.comPraxis Precision Medicines Shares Fall as Seizure Treatment Fails to Meet Trial's Primary Endpoint -- UpdateJune 1, 2026 | marketwatch.comPraxis Precision's epilepsy drug misses main goal of mid-to-late stage studyJune 1, 2026 | reuters.comPraxis Precision Reassesses Vormatrigine After Mixed POWER1 DataJune 1, 2026 | tipranks.comPraxis Precision Medicines Provides Vormatrigine Program UpdateJune 1, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)May 28, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLYS, ABVX, PRAX, and CYTK Company DescriptionsAbivax NASDAQ:ABVX$101.53 -3.40 (-3.24%) Closing price 04:00 PM EasternExtended Trading$100.75 -0.78 (-0.77%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Cytokinetics NASDAQ:CYTK$71.48 -0.81 (-1.12%) Closing price 04:00 PM EasternExtended Trading$71.32 -0.17 (-0.23%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Mineralys Therapeutics NASDAQ:MLYS$23.69 -1.36 (-5.43%) Closing price 04:00 PM EasternExtended Trading$23.74 +0.05 (+0.21%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Praxis Precision Medicines NASDAQ:PRAX$254.00 -10.75 (-4.06%) Closing price 04:00 PM EasternExtended Trading$249.52 -4.47 (-1.76%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
